Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.47 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.47 |
| ▸ | LMNA | P02545 | 4/20 | 0.45 |
| ▸ | CES1 | P23141 | 4/20 | 0.45 |
| ▸ | CES2 | O00748 | 3/20 | 0.45 |
| ▸ | HPGD | P15428 | 2/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.45 |
| ▸ | ALPG | P10696 | 1/20 | 0.45 |
| ▸ | MDM2 | Q00987 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.41 |
| ▸ | USP2 | O75604 | 1/20 | 0.41 |
| ▸ | HTT | P42858 | 1/20 | 0.41 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.41 |
| ▸ | TSHR | P16473 | 3/20 | 0.41 |
| ▸ | DAO | P14920 | 1/20 | 0.41 |
| ▸ | NAPRT | Q6XQN6 | 1/20 | 0.41 |
| ▸ | ALKBH5 | Q6P6C2 | 1/20 | 0.39 |
| ▸ | PGR | P06401 | 1/20 | 0.39 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | ADRA2B | P18089 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29237750 | 1.00 | TDP1 (0.47) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL25342452 | 0.80 | CES2 (0.45) | L3MBTL1LMNACES1CES2MDM2 | |
| SCHEMBL408412 | 0.78 | TDP1 (0.50) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL23091851 | 0.78 | TDP1 (0.50) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL7342834 | 0.77 | LMNA (0.52) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL395491 | 0.77 | MDM2 (0.48) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL740027 | 0.76 | CES1 (0.45) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL740918 | 0.75 | TDP1 (0.47) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL10741256 | 0.75 | TDP1 (0.47) | TDP1L3MBTL1LMNACES1CES2 | |
| SCHEMBL741168 | 0.75 | PGR (0.47) | TDP1L3MBTL1LMNACES1CES2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-110526867-A | A method of efficiently preparing blonanserin intermediate | HUNAN XIANGZHONG PHARMACEUTICAL CO LTD | 2019-12-03 | — | — | CN | claimed |
| CN-107056653-B | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2019-07-09 | — | — | CN | claimed |
| CN-107056653-A | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2017-08-18 | — | — | CN | claimed |
| CN-105272883-A | Preparation method for high-purity 4-fluorobenzoylacetonitrile | TIANJIN KELAI BORUI TECHNOLOGY CO LTD | 2016-01-27 | — | — | CN | claimed |
| CN-118239862-A | Chiral monofluorone carbonyl substituted nitrile compound and preparation method and application thereof | 上海应用技术大学 | 2024-06-25 | — | — | CN | disclosed |
| EP-2970141-B1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON CORP (US) | 2020-02-26 | — | — | EP | disclosed |
| CN-110526867-A | A method of efficiently preparing blonanserin intermediate | HUNAN XIANGZHONG PHARMACEUTICAL CO LTD | 2019-12-03 | — | — | CN | disclosed |
| CN-110526867-A | A method of efficiently preparing blonanserin intermediate | HUNAN XIANGZHONG PHARMACEUTICAL CO LTD | 2019-12-03 | — | — | CN | disclosed |
| CN-107056653-B | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-107056653-B | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2019-07-09 | — | — | CN | disclosed |
| CN-107056653-B | Synthetic method of the blonanserin intermediate to fluorobenzoyl acetonitrile | 丽珠医药集团股份有限公司 | 2019-07-09 | — | — | CN | disclosed |
| US-20180186751-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON INTERNATIONAL CORPORATION | 2018-07-05 | — | — | US | disclosed |
| WO-2014146059-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | VERSEON, INC. (US) | 2014-09-18 | — | — | WO | disclosed |
| CN-102762560-A | Disubstituted heteroaryl-fused pyridines | NOVARTIS AG | 2012-10-31 | — | — | CN | disclosed |
| CN-102459280-A | Thieno [2,3-b ] pyridine derivatives as inhibitors of viral replication | UNIV LEUVEN KATH | 2012-05-16 | — | — | CN | disclosed |
| EP-2430029-A1 | THIENO [2, 3-B]PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | Katholieke Universiteit Leuven (BE) | 2012-03-21 | — | — | EP | disclosed |
| WO-2010130842-A1 | THIENO [2, 3-B] PYRIDINE DERIVATIVES AS VIRAL REPLICATION INHIBITORS | KATHOLIEKE UNIVERSITEIT LEUVEN (BE) | 2010-11-18 | — | — | WO | disclosed |
| CN-1872859-A | Compound of heterocyclic pyridine class | WANG SONGFA (CN) | 2006-12-06 | — | — | CN | disclosed |
| EP-0195396-A1 | 5-Fluorobenzonitrile derivatives and pharmacologically acceptable acid addition salts thereof for increasing the lean meat to fat ratio, and/or enhancing the growth rate of warm-blooded animals | AMERICAN CYANAMID COMPANY (US) | 1986-09-24 | — | — | EP | disclosed |
| EP-0016277-A1 | 2-Carbonyl-3-hydroxy-alkenonitriles, their use as anti-arthritic agents and processes for their preparation | AMERICAN CYANAMID COMPANY (US) | 1980-10-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180186751-A1 | HALOGENOPYRAZOLES AS INHIBITORS OF THROMBIN | F2, TFPI, SERPINC1 | TDP1 356/4885L3MBTL1 1464/4885LMNA 1086/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.